Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

Conditions

• OAG - Open-Angle Glaucoma
• OHT - Ocular Hypertension

Eligibility Criteria

Sex

ALL

Age

12 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• QLS-111-FDC — COMBINATION_PRODUCT
  QLS-111-FDC, a PF FDC administered by topical ophthalmic (TO) application for 14 days in the evening (QPM) in both eyes (OU).
• Latanoprost (0.005%) — DRUG
  PF latanoprost administered by TO application for 14 days QPM OU.

Study Details

Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Key Dates

Start date

Mar 18, 2026

Status verified

Mar 2026

Primary completion

Jul 1, 2026

Completion

Jul 15, 2026

Study Design

Enrollment

60 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: QLS-111-FDC ophthalmic solution
  QLS-111-FDC, PF FDC
• Active Comparator: Latanoprost ophthalmic solution
  PF latanoprost 0.005%

Primary Outcome Measure

Change from baseline in IOP [ Time Frame: Over 15 days ]

Central Contacts

• Lisa Brandano
  9789302103
  [email protected]
• Lauryl Hargreaves
  [email protected]

Locations (1)

Find similar trials in Largo, FL